// App-Quantinova.ai

641 : Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study

Researchers

Presenter

  • Ana Maia

Principal Investigators

  • Joao Gamelas Magalhaes

  • David Reardon

  • Ahmed Idbaih

  • Maria Vieito

  • Ghazaleh Tabatabai

  • Agostina Stradella

  • Francois Ghiringhelli

  • Michael C Burger

  • Iris Mildenberger

  • Ulrich Herrlinger

  • Macarena Gonzalez

  • Alice Hervieu

  • Marta GilMartin

  • Mirjam Renovanz

  • Mehdi Touat

  • Patrick Y Wen

  • Antje Wick

  • Laurent Chene

  • Cecile Gouttefangeas

  • Christophe Bonny

  • Jan Fagerberg

  • Wolfgang Wick

Medical Centers

  • Hopital Universitaire Pitie-Salpetriere, Paris, France

  • Institut Català d'Oncologia L’Hospitalet,Barcelona,Spain

  • Eberhard Karls University, Tubingen, Germany

  • Universitatsklinik Frankfurt Hospital, Frankfurt, Germany

  • Universitätsklinikum Heidelberg Cancer, Heidelberg, Germany

  • Universitatsklinikum Bonn, Bonn, Germany

  • Hospital Universitari Vall -Hebron. Ciberehd., Barcelona, Spain

  • Medizinische Fakultät Mannheim, Mannheim, Germany

  • Enterome, Paris, France

  • Dana-Farber Cancer Institute, Boston, MA

  • Center Georges-Francois Leclerc, Dijon, France

Locations

  • France

  • Germany

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • Temozolomide

  • Bevacizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT04116658

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved